Biopharmx Corp (NASDAQ:BPMX) was down 7.1% on Monday . The stock traded as low as $0.19 and last traded at $0.19. Approximately 883,879 shares were traded during mid-day trading, a decline of 17% from the average daily volume of 1,061,490 shares. The stock had previously closed at $0.21.
Several equities research analysts have weighed in on BPMX shares. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research report on Wednesday, September 13th. Maxim Group restated a “buy” rating and issued a $1.50 price objective (down previously from $3.00) on shares of Biopharmx Corp in a research report on Wednesday, September 13th.
The company’s market capitalization is $15.06 million. The firm’s 50 day moving average is $0.27 and its 200-day moving average is $0.42.
Biopharmx Corp (NASDAQ:BPMX) last posted its earnings results on Wednesday, September 13th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. On average, equities analysts forecast that Biopharmx Corp will post ($0.24) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC raised its holdings in Biopharmx Corp by 10.0% in the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after buying an additional 1,282,052 shares during the last quarter. Virtu KCG Holdings LLC raised its holdings in Biopharmx Corp by 366.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after buying an additional 395,424 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Biopharmx Corp by 324.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after buying an additional 1,478,338 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Biopharmx Corp (BPMX) Trading Down 7.1%” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/01/biopharmx-corp-bpmx-trading-down-7-1.html.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
What are top analysts saying about Biopharmx Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biopharmx Corp and related companies.